ZA9610020B - Heterocyclic compounds - Google Patents

Heterocyclic compounds

Info

Publication number
ZA9610020B
ZA9610020B ZA9610020A ZA9610020A ZA9610020B ZA 9610020 B ZA9610020 B ZA 9610020B ZA 9610020 A ZA9610020 A ZA 9610020A ZA 9610020 A ZA9610020 A ZA 9610020A ZA 9610020 B ZA9610020 B ZA 9610020B
Authority
ZA
South Africa
Prior art keywords
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
ZA9610020A
Inventor
Heinrich Rueger
Tibur Schmidlin
Pascal Rigollier
Yasuchika Yamaguchi
Marina Tintelnot-Blomley
Walter Schilling
Leoluca Criscione
Robert Mah
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of ZA9610020B publication Critical patent/ZA9610020B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9610020A 1995-12-01 1996-11-28 Heterocyclic compounds ZA9610020B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56637895A 1995-12-01 1995-12-01

Publications (1)

Publication Number Publication Date
ZA9610020B true ZA9610020B (en) 1997-06-01

Family

ID=24262639

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9610020A ZA9610020B (en) 1995-12-01 1996-11-28 Heterocyclic compounds

Country Status (3)

Country Link
AU (1) AU7692996A (en)
WO (1) WO1997020823A2 (en)
ZA (1) ZA9610020B (en)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6309698A (en) * 1997-03-12 1998-09-29 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient
GB9709815D0 (en) * 1997-05-14 1997-07-09 Merck Sharp & Dohme Therapeutic method
WO1999001128A1 (en) * 1997-07-03 1999-01-14 Neurogen Corporation Certain diarylimidazole derivatives; a new class of npy specific ligands
WO1999010330A1 (en) * 1997-08-25 1999-03-04 Bayer Corporation Heterocyclic ketones as npy y5 antagonists
WO1999027965A1 (en) * 1997-11-28 1999-06-10 Banyu Pharmaceutical Co., Ltd. Antihyperlipemic agents
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO1999055667A1 (en) * 1998-04-29 1999-11-04 Ortho-Mcneil Pharmaceutical, Inc. N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
AU756797B2 (en) 1998-11-10 2003-01-23 Banyu Pharmaceutical Co., Ltd. Spiro-indolines as Y5 receptor antagonists
US6407120B1 (en) 1999-02-18 2002-06-18 Pfizer Inc. Neuropeptide Y antagonists
EP1184373A4 (en) 1999-04-20 2004-10-20 Meiji Seika Kaisha Tricyclic compounds
WO2000064880A1 (en) 1999-04-22 2000-11-02 Synaptic Pharmaceutical Corporation Selective npy (y5) antagonists
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
US6989379B1 (en) 1999-04-22 2006-01-24 H. Lundbick A/S Selective NPY (Y5) antagonists
US6218408B1 (en) 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
MXPA01011321A (en) * 1999-05-05 2003-08-01 Johnson & Johnson 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS.
US6841552B1 (en) 1999-05-05 2005-01-11 Ortho-Mcneil Pharmaceutical, Inc. 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders
US6225330B1 (en) 1999-06-30 2001-05-01 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US6222040B1 (en) 1999-06-30 2001-04-24 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US6214853B1 (en) 1999-06-30 2001-04-10 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
US6608227B1 (en) 1999-10-15 2003-08-19 Bristol-Myers Squibb Pharma Benzylcycloalkyl amines as modulators of chemokine receptor activity
US6291499B1 (en) * 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
DK2014285T3 (en) * 1999-11-26 2010-06-28 Shionogi & Co NPYY5 receptor antagonists
SV2002000522A (en) 2000-07-13 2002-10-24 Lilly Co Eli BETA3 ADRENERGIC AGOSNIST REF. X-13921
CA2460594A1 (en) * 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Mch receptor antagonists
CA2403307A1 (en) * 2001-10-23 2003-04-23 Neurogen Corporation Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
ES2193875B2 (en) 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. DERIVATIVES OF BENZOXAZINONA, ITS PREPARATION AND ITS APPLICATION AS MEDICATIONS.
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
EP1407774A1 (en) * 2002-09-10 2004-04-14 LION Bioscience AG 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
EP1398032A1 (en) * 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-Oxo-quinazolines as LXR nuclear receptor binding compounds
US7589207B2 (en) 2002-12-13 2009-09-15 Smithkline Beecham Corporation Cyclohexyl compounds as CCR5 antagonists
EP1589960A4 (en) * 2002-12-19 2008-09-10 Scios Inc Treatment of obesity and associated conditions with tgf-beta inhibitors
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20070010671A1 (en) * 2003-03-31 2007-01-11 Yoshinori Sekiguchi Novel quinazoline derivatives and methods of treatment related to the use thereof
JP2004315511A (en) * 2003-03-31 2004-11-11 Taisho Pharmaceut Co Ltd Mch receptor antagonist
JP4806628B2 (en) 2003-05-05 2011-11-02 プロビオドルグ エージー Glutaminyl cyclase inhibitor
WO2004111014A1 (en) * 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
ES2222833B1 (en) 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 1,4-DISPOSED PIPERIDINIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICINES.
EP1669350B1 (en) 2003-09-22 2012-02-29 Msd K.K. Piperidine derivatives
JP2007510629A (en) 2003-10-22 2007-04-26 イーライ リリー アンド カンパニー Novel MCH receptor antagonist
JP2007509898A (en) 2003-11-03 2007-04-19 プロビオドルグ エージー Useful combinations for the treatment of neurological disorders
GB0400193D0 (en) * 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
EP1713780B1 (en) 2004-02-05 2012-01-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
CN1976905A (en) * 2004-03-30 2007-06-06 大正制药株式会社 Pyrimidine derivatives and methods of treatment related to the use thereof
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
CA2571937A1 (en) * 2004-07-08 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of pkc-theta
US20090156474A1 (en) 2004-11-01 2009-06-18 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc Compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
KR101397913B1 (en) 2005-05-30 2014-05-26 엠에스디 가부시키가이샤 Novel piperidine derivative
NZ564222A (en) 2005-06-14 2011-10-28 Taigen Biotechnology Co Ltd Pyrimidine compounds
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
AU2006277253A1 (en) 2005-08-10 2007-02-15 Msd K.K. Pyridone compound
CA2617649A1 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
BRPI0614649A2 (en) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc hybrid polypeptides with selectable properties
WO2007024004A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
JPWO2007029847A1 (en) 2005-09-07 2009-03-19 萬有製薬株式会社 Bicyclic aromatic substituted pyridone derivatives
JP4879988B2 (en) 2005-09-29 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US20080255084A1 (en) 2005-10-21 2008-10-16 Randy Lee Webb Combination of Organic Compounds
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
JP4371164B2 (en) 2005-11-10 2009-11-25 萬有製薬株式会社 Aza-substituted spiro derivatives
WO2007125952A1 (en) 2006-04-28 2007-11-08 Shionogi & Co., Ltd. Amine derivative having npy y5 receptor antagonist activity
CA2770486C (en) 2006-09-22 2014-07-15 Merck Sharp & Dohme Corp. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
EP2072519A4 (en) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd Diaryl ketimine derivative
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN101668525A (en) 2007-03-01 2010-03-10 前体生物药物股份公司 New use of glutaminyl cyclase inhibitors
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
DK2142514T3 (en) 2007-04-18 2015-03-23 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
EA020466B1 (en) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
SA08290668B1 (en) 2007-10-25 2012-02-12 شيونوجي آند كو.، ليمتد Amine Derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
PE20091309A1 (en) * 2007-12-21 2009-09-30 Astrazeneca Ab CYCLOHEXYL DERIVATIVES AS ACETYL COENZYME CARBOXYLASE INHIBITORS
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
WO2009119726A1 (en) 2008-03-28 2009-10-01 萬有製薬株式会社 Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
PL2268635T3 (en) 2008-04-21 2015-11-30 Taigen Biotechnology Co Ltd Heterocyclic compounds
CL2009000904A1 (en) 2008-04-21 2010-04-30 Shionogi & Co Compounds derived from cyclohexyl sulfonamides having antagonist activity at the npy y5 receptor, pharmaceutical composition and pharmaceutical formulation comprising them.
JP2011522828A (en) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
CA2727914A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diaryl ketoxime derivative technical field
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
NZ592544A (en) 2008-10-30 2013-01-25 Merck Sharp & Dohme Isonicotinamide orexin receptor antagonists
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
TW201021855A (en) 2008-11-13 2010-06-16 Taigen Biotechnology Co Ltd Lyophilization formulation
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
JP5685181B2 (en) * 2009-03-05 2015-03-18 塩野義製薬株式会社 Cyclohexane derivative having NPYY5 receptor antagonistic action
US8227618B2 (en) 2009-04-23 2012-07-24 Shionogi & Co., Ltd. Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
SG178592A1 (en) * 2009-09-03 2012-04-27 Bristol Myers Squibb Co Quinazolines as potassium ion channel inhibitors
JP5934645B2 (en) 2009-09-11 2016-06-15 プロビオドルグ エージー Heterocyclic derivatives as glutaminyl cyclase inhibitors
EP2538784B1 (en) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazole derivatives useful anti-diabetic agents
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
CN102791704B (en) 2010-03-10 2015-11-25 前体生物药物股份公司 The heterocycle inhibitor of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
US8748433B2 (en) 2010-04-30 2014-06-10 Merck Sharp & Dohme Corp. β3 adrenergic receptor agonists
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
JP6050264B2 (en) 2011-03-16 2016-12-21 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
JP2015525782A (en) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Antidiabetic tricyclic compounds
CN104994848A (en) 2013-02-22 2015-10-21 默沙东公司 Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP2016514670A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase receptor agonists in combination with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
KR102272746B1 (en) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2017002610A (en) 2014-08-29 2017-10-11 Tes Pharma S R L INHIBITORS OF A-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE.
CA3038185A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
DK3461819T3 (en) 2017-09-29 2020-08-10 Probiodrug Ag GLUTAMINYL CYCLASE INHIBITORS
AU2019385644A1 (en) 2018-11-20 2021-06-03 Tes Pharma S.R.L. Inhibitors of α-Amino-β-carboxymuconic acid semialdehyde decarboxylase
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
KR20220066252A (en) 2019-07-11 2022-05-24 프락시스 프리시젼 메디신즈, 인크. Formulation of type T calcium channel modulator and method of use thereof
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
AU2021329805B2 (en) 2020-08-18 2024-02-29 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists
CN114315802B (en) * 2021-12-14 2023-06-16 西安医学院 Quinazoline nitrogen-containing heterocyclic derivative, preparation method and application
KR20230098496A (en) * 2021-12-24 2023-07-04 아주대학교산학협력단 Novel compound for improving sleep and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
DK0448765T3 (en) * 1990-03-30 1994-09-19 Heumann Pharma Gmbh & Co Use of guanidine derivatives for the preparation of a drug with NPY antagonistic effect
KR930702292A (en) * 1990-11-06 1993-09-08 알렌 제이. 스피겔 Quinazolin derivatives for enhancing tumor therapeutic activity
FR2701480B1 (en) * 1993-02-15 1995-05-24 Sanofi Elf Compounds with a sulfamoyl and amidino group, process for their preparation and pharmaceutical compositions containing them.
EP0895781A3 (en) * 1994-10-20 1999-07-07 Eli Lilly And Company Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins

Also Published As

Publication number Publication date
WO1997020823A3 (en) 1997-07-17
WO1997020823A2 (en) 1997-06-12
AU7692996A (en) 1997-06-27

Similar Documents

Publication Publication Date Title
EG24195A (en) Heterocyclic compounds
ZA9610020B (en) Heterocyclic compounds
GB9512697D0 (en) Heterocyclic compounds
GB9518552D0 (en) New heterocyclic compounds
PL322722A1 (en) Novel heterocyclic compounds
GB9504361D0 (en) Heterocyclic compounds
GB9408872D0 (en) Heterocyclic compounds
GB9413758D0 (en) Heterocyclic compounds
PL325637A1 (en) Novel heterocyclic compounds
GB9401921D0 (en) Heterocyclic compounds
GB9401994D0 (en) Heterocyclic compounds
ZA962734B (en) Heterocyclic compounds
ZA968551B (en) Heterocyclic compounds
ZA964615B (en) Heterocyclic compounds
GB9515085D0 (en) Heterocyclic compounds
ZA962732B (en) Heterocyclic compounds
ZA962733B (en) Heterocyclic compounds
ZA962736B (en) Heterocyclic compounds
ZA962737B (en) Heterocyclic compounds
ZA962738B (en) Heterocyclic compounds
GB9515302D0 (en) Heterocyclic compounds
ZA968094B (en) Heterocyclic compounds
GB9511072D0 (en) Heterocyclic compounds
GB9504839D0 (en) Heterocyclic compounds
GB9504383D0 (en) Heterocyclic compounds